Anti-infliximab antibodies are already detectable in most patients with rheumatoid arthritis halfway through an infusioncycle: an open-label pharmacokinetic cohort study
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2474
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Anti-infliximab antibodies are already detectable in most patients with rheumatoid arthritis halfway through an infusioncycle: an open-label pharmacokinetic cohort study ; volume:12 ; number:1 ; day:13 ; month:1 ; year:2011 ; pages:1-6 ; date:12.2011
BMC musculoskeletal disorders ; 12, Heft 1 (13.1.2011), 1-6, 12.2011
- Urheber
-
van den Bemt, Bart JF
- Beteiligte Personen und Organisationen
-
den Broeder, Alfons A.
Wolbink, GJ
Hekster, Yechiel A.
van Riel, Piet LCM
Benraad, Bart
van den Hoogen, Frank HJ
SpringerLink (Online service)
- DOI
-
10.1186/1471-2474-12-12
- URN
-
urn:nbn:de:1111-2016043018296
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:48 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- van den Bemt, Bart JF
- den Broeder, Alfons A.
- Wolbink, GJ
- Hekster, Yechiel A.
- van Riel, Piet LCM
- Benraad, Bart
- van den Hoogen, Frank HJ
- SpringerLink (Online service)
Ähnliche Objekte (12)
Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis
Infliximab in ankylosing spondylitis: alone or in combination with methotrexate? A pharmacokinetic comparative study
Open-label, phase I, pharmacokinetic studies of abiraterone acetate in healthy men
Pharmacokinetic Effects of Antidrug Antibodies Occurring in Healthy Subjects After a Single Dose of Intravenous Infliximab
Are you coordinating already?
We have *already* started
Performance of Eight Infliximab Population Pharmacokinetic Models in a Cohort of Dutch Children with Inflammatory Bowel Disease
Infliximab for pediatric patients with ulcerative colitis: a phase 3, open-label, uncontrolled, multicenter trial in Japan
Primary lack of efficacy of infliximab therapy for rheumatoid arthritis: pharmacokinetic characterization and assessment of switching to tocilizumab
Treatment Targets Should Influence Choice of Infliximab Dose Intensification Strategy in Inflammatory Bowel Disease: A Pharmacokinetic Simulation Study
Functional Programming You Already Know
An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody status
Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis
Infliximab in ankylosing spondylitis: alone or in combination with methotrexate? A pharmacokinetic comparative study
Open-label, phase I, pharmacokinetic studies of abiraterone acetate in healthy men
Pharmacokinetic Effects of Antidrug Antibodies Occurring in Healthy Subjects After a Single Dose of Intravenous Infliximab
Are you coordinating already?
We have *already* started
Performance of Eight Infliximab Population Pharmacokinetic Models in a Cohort of Dutch Children with Inflammatory Bowel Disease
Infliximab for pediatric patients with ulcerative colitis: a phase 3, open-label, uncontrolled, multicenter trial in Japan
Primary lack of efficacy of infliximab therapy for rheumatoid arthritis: pharmacokinetic characterization and assessment of switching to tocilizumab
Treatment Targets Should Influence Choice of Infliximab Dose Intensification Strategy in Inflammatory Bowel Disease: A Pharmacokinetic Simulation Study
Functional Programming You Already Know
An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody status
Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis
Infliximab in ankylosing spondylitis: alone or in combination with methotrexate? A pharmacokinetic comparative study
Open-label, phase I, pharmacokinetic studies of abiraterone acetate in healthy men
Pharmacokinetic Effects of Antidrug Antibodies Occurring in Healthy Subjects After a Single Dose of Intravenous Infliximab
Are you coordinating already?
We have *already* started
Performance of Eight Infliximab Population Pharmacokinetic Models in a Cohort of Dutch Children with Inflammatory Bowel Disease
Infliximab for pediatric patients with ulcerative colitis: a phase 3, open-label, uncontrolled, multicenter trial in Japan
Primary lack of efficacy of infliximab therapy for rheumatoid arthritis: pharmacokinetic characterization and assessment of switching to tocilizumab
Treatment Targets Should Influence Choice of Infliximab Dose Intensification Strategy in Inflammatory Bowel Disease: A Pharmacokinetic Simulation Study
Functional Programming You Already Know